H.C. Wainwright reiterates Buy rating on Astria Therapeutics stock at $20
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Astria Therapeutics, setting a target price of $20 for the stock. This endorsement reflects confidence in the company's potential and could attract more investors, signaling a positive outlook for Astria's future performance in the market.
— Curated by the World Pulse Now AI Editorial System